Cet anticorp SARS-CoV-2 Spike S2 est conjugé à/à la Biotin
Application
Veuillez nous consulter SVP
Purification
SARS-CoV-2 (COVID-19) Spike Antibody (biotin) is affinity chromatography purified via peptide column.
Immunogène
Anti-SARS-CoV-2 (COVID-19) Spike S2 antibody (biotin) was raised against a peptide corresponding to 16 amino acids near the carboxy terminus of SARS-CoV-2 (COVID-19) Spike glycoprotein. The immunogen is located within 1130-1180 amino acids of SARS-CoV-2 (COVID-19) Spike protein.
Reactivité: SARS Coronavirus-2 (SARS-CoV-2)
ELISA
Hôte: Lapin
Polyclonal
Biotin
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
SARS-CoV-2 (COVID-19) Spike Antibody (biotin) is supplied in PBS containing 0.02 % sodium azide.
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
-20 °C,4 °C
Stockage commentaire
SARS-CoV-2 (COVID-19) Spike antibody (biotin) can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
anticorps E2, anticorps Surface Glycoprotein, anticorps S
Classe de substances
Viral Protein
Sujet
Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019-20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).